A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Pfizer Inc stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 2,620,014 shares of PFE stock, worth $75.9 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
2,620,014
Previous 2,445,045 7.16%
Holding current value
$75.9 Million
Previous $67.8 Million 8.04%
% of portfolio
0.25%
Previous 0.25%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.26 - $29.6 $4.42 Million - $5.18 Million
174,969 Added 7.16%
2,620,014 $73.3 Million
Q1 2024

May 14, 2024

SELL
$25.89 - $29.73 $3.89 Million - $4.47 Million
-150,264 Reduced 5.79%
2,445,045 $67.8 Million
Q4 2023

Feb 13, 2024

BUY
$26.13 - $33.94 $8.4 Million - $10.9 Million
321,372 Added 14.13%
2,595,309 $74.7 Million
Q3 2023

Nov 13, 2023

BUY
$32.09 - $37.51 $10.9 Million - $12.7 Million
339,589 Added 17.56%
2,273,937 $75.4 Million
Q2 2023

Aug 14, 2023

BUY
$36.12 - $41.79 $17.3 Million - $20 Million
479,118 Added 32.92%
1,934,348 $71 Million
Q1 2023

May 12, 2023

BUY
$39.39 - $51.28 $13.3 Million - $17.4 Million
338,600 Added 30.32%
1,455,230 $59.4 Million
Q4 2022

Feb 13, 2023

BUY
$41.75 - $54.5 $12.8 Million - $16.7 Million
306,770 Added 37.88%
1,116,630 $57.2 Million
Q3 2022

Nov 10, 2022

SELL
$43.76 - $53.42 $422,809 - $516,144
-9,662 Reduced 1.18%
809,860 $35.4 Million
Q2 2022

Aug 12, 2022

BUY
$46.53 - $55.17 $29.6 Million - $35.1 Million
636,200 Added 347.04%
819,522 $43 Million
Q1 2022

May 13, 2022

SELL
$45.75 - $56.69 $7.98 Million - $9.88 Million
-174,323 Reduced 48.74%
183,322 $9.49 Million
Q4 2021

Feb 11, 2022

SELL
$41.32 - $61.25 $18.9 Million - $28 Million
-457,535 Reduced 56.13%
357,645 $21.1 Million
Q3 2021

Nov 12, 2021

BUY
$39.25 - $50.42 $2.14 Million - $2.75 Million
54,450 Added 7.16%
815,180 $35.1 Million
Q2 2021

Aug 12, 2021

BUY
$35.91 - $40.68 $13.7 Million - $15.5 Million
381,545 Added 100.62%
760,730 $29.8 Million
Q1 2021

May 13, 2021

BUY
$33.49 - $37.77 $7.17 Million - $8.08 Million
214,000 Added 129.55%
379,185 $13.7 Million
Q4 2020

Feb 12, 2021

SELL
$33.47 - $42.56 $686,135 - $872,480
-20,500 Reduced 11.04%
165,185 $6.08 Million
Q3 2020

Nov 13, 2020

BUY
$31.75 - $37.25 $79,375 - $93,125
2,500 Added 1.36%
185,685 $6.82 Million
Q2 2020

Aug 13, 2020

SELL
$30.12 - $36.54 $2.87 Million - $3.48 Million
-95,338 Reduced 34.23%
183,185 $5.99 Million
Q1 2020

May 14, 2020

SELL
$27.03 - $38.62 $2.58 Million - $3.68 Million
-95,286 Reduced 25.49%
278,523 $9.09 Million
Q4 2019

Feb 13, 2020

SELL
$32.92 - $37.36 $5.47 Million - $6.2 Million
-166,040 Reduced 30.76%
373,809 $14.6 Million
Q3 2019

Nov 13, 2019

BUY
$32.49 - $42.13 $770,240 - $998,775
23,707 Added 4.59%
539,849 $19.4 Million
Q2 2019

Aug 13, 2019

BUY
$36.98 - $41.52 $195,809 - $219,848
5,295 Added 1.04%
516,142 $22.4 Million
Q1 2019

May 14, 2019

SELL
$37.5 - $41.2 $10 Million - $11 Million
-267,032 Reduced 34.33%
510,847 $21.7 Million
Q4 2018

Feb 13, 2019

SELL
$38.47 - $43.86 $9.7 Million - $11.1 Million
-252,253 Reduced 24.49%
777,879 $34 Million
Q3 2018

Nov 14, 2018

SELL
$34.47 - $41.81 $67.5 Million - $81.8 Million
-1,957,072 Reduced 65.52%
1,030,132 $45.4 Million
Q2 2018

Aug 14, 2018

SELL
$32.98 - $35.16 $42.7 Million - $45.5 Million
-1,294,909 Reduced 30.24%
2,987,204 $108 Million
Q1 2018

May 15, 2018

BUY
$31.91 - $37.02 $8.39 Million - $9.73 Million
262,816 Added 6.54%
4,282,113 $152 Million
Q4 2017

Feb 14, 2018

SELL
$33.26 - $35.29 $4.04 Million - $4.29 Million
-121,500 Reduced 2.93%
4,019,297 $146 Million
Q3 2017

Nov 14, 2017

SELL
$31.0 - $34.15 $19.9 Million - $21.9 Million
-642,580 Reduced 13.43%
4,140,797 $148 Million
Q2 2017

Aug 14, 2017

BUY
N/A
4,783,377
4,783,377 $161 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $163B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track Jeremy Grantham's Portfolio

Track Jeremy Grantham Portfolio

Follow Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.